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1. Context
Thrombus embolization during percutaneous coronary inter-
vention (PCI) in ST-segment elevation myocardial infarction
(STEMI) is common and results in suboptimal myocardial
perfusion and increased infarct size. Two strategies proposed
to reduce distal embolization and improve outcomes after
primary PCI are bolus intracoronary abciximab and manual
aspiration thrombectomy.
2. Objective
To determine whether bolus intracoronary abciximab, man-
ual aspiration thrombectomy, or both reduce infarct size in
high-risk patients with STEMI.
3. Design, setting, and patients
Between November 28, 2009, and December 2, 2011, 452
patients presenting at 37 sites in 6 countries within 4 h of
STEMI due to proximal or mid left anterior descending artery
occlusion undergoing primary PCI with bivalirudin anti-
coagulation were randomized in an open-label, 22 factorial
design to bolus intracoronary abciximab delivered locally at
the infarct lesion site vs no abciximab and to manual aspira-
tion thrombectomy vs no thrombectomy.
4. Interventions
A 0.25 mg/kg bolus of abciximab was administered at the site
of the infarct lesion via a local drug delivery catheter. Manual
aspiration thrombectomywas performedwith a 6 F aspiration
catheter.
5. Main outcome measures
Primary end point: infarct size (percentage of total left ven-
tricular mass) at 30 days assessed by cardiac magneticresonance imaging (cMRI) in the abciximab vs no abciximab
groups (pooled across the aspiration randomization); major
secondary end point: 30-day infarct size in the aspiration vs
no aspiration groups (pooled across the abciximab
randomization).
6. Results
Evaluable cMRI results at 30 days were present in 181 and 172
patients randomized to intracoronary abciximab vs no
abciximab, respectively, and in 174 and 179 patients
randomized to manual aspiration vs. no aspiration, respec-
tively. Patients randomized to intracoronary abciximab
compared with no abciximab had a significant reduction in
30-day infarct size (median, 15.1%; interquartile range [IQR],
6.8%e22.7%; n ¼ 181, vs. 17.9% [IQR, 10.3%e25.4%]; n ¼ 172;
p ¼ 0.03). Patients randomized to intracoronary abciximab
also had a significant reduction in absolute infarct mass
(median, 18.7 g [IQR, 7.4e31.3 g]; n ¼ 184, vs. 24.0 g [IQR,
12.1e34.2 g]; n ¼ 175; p ¼ 0.03) but not abnormal wall motion
score (median, 7.0 [IQR, 2.0e10.0]; n ¼ 188, vs. 8.0 [IQR,
3.0e10.0]; n ¼ 184; p ¼ 0.08). Patients randomized to aspiration
thrombectomy vs no aspiration had no significant difference
in infarct size at 30 days (median, 17.0% [IQR, 9.0%e22.8%];
n¼ 174, vs. 17.3% [IQR, 7.1%e25.5%]; n¼ 179; p¼ 0.51), absolute
infarctmass (median, 20.3 g [IQR, 9.7e31.7 g]; n¼ 178, vs. 21.0 g
[IQR, 9.1e34.1 g]; n ¼ 181; p ¼ 0.36), or abnormal wall motion
score (median, 7.5 [IQR, 2.0e10.0]; n ¼ 186, vs. 7.5 [IQR,
2.0e10.0]; n ¼ 186; p ¼ 0.89).
7. Conclusion
In patients with large anterior STEMI presenting early after
symptom onset and undergoing primary PCI with bivalirudin
anticoagulation, infarct size at 30 days was significantly
reduced by bolus intracoronary abciximab delivered to
the infarct lesion site but not by manual aspiration
thrombectomy.
8. Perspective
In this multicenter, prospective, randomized trial in patients
with large anterior STEMI presenting early after infarct onset
and undergoing primary PCI with bivalirudin anticoagulation,
the principal findings were: 1) bolus intracoronary abciximab
delivered to the site of the lesion via a clearway catheter sig-
nificantly but modestly reduced the infarct size at 30 days 2)
thrombus aspiration with export catheter had no effect on
infarct size and 3) indices of myocardial reperfusion, ST
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thrombosis/bleeding were not significantly different between
the randomized groups.
Two of the strongest baseline determinants of infarct size
are: 1) anterior MI location and 2) abnormal TIMI flow. This
trial was limited to patients with proximal or mid LAD
occlusion and TIMI 0e2 flow. Moreover, it only enrolled
patients who could be treated early, in whom timewindow for
effective myocardial salvage had not closed. The median time
from symptom onset to hospital arrival was only 99 min and
the median D-to-B time was 45 min. Thus the study pop-
ulation represents a highly selected cohort of patients with
large anterior MI, in whom infarct size reduction should be
feasible given early presentation and rapid treatment. Infarct
size was assessed by cMRI, which strongly correlates with
subsequent mortality. Unlike prior studies, which measured
infarct size at 2e7 days (a period during which substantial
myocardial edema is present, thereby interfering with
assessment of viable myocardium) in this study cMRI was
done at 30 days when much of myocardial edema had
resolved.
These results need to be placed in the context of previous
studies. A meta-analysis of 6 RCT’s (1246 patients) reported
enhanced survival with bolus intracoronary abciximab.
However, the recent AIDA-STEMI trial (2065 patients) found
nearly identical rates of MACE with bolus intracoronary and
intravenous abciximab. However, this trial differs from these
earlier studies in many ways: 1) unlike prior studies which
included routine post-PCI intravenous abciximab infusion in
both the groups, in this trial only bolus intracoronary abcix-
imabwas given in the randomized groups. 2) In all prior trials
(including AIDA-STEMI), intracoronary abciximabwas infused
proximally through the guide catheter thereby limiting its
penetration into occlusive thrombus and allowing spillage of
the drug to LCx or backflow into the aorta. In contrast, the
local drug delivery catheter (clearway catheter) used in this
study achieves high intra-clot concentration of abciximab at
the site of LAD occlusion and prolongs drug residence time,
which may enhance platelet disaggregation and thrombus
resolution. In the present study, an abciximab bolus delivered
directly to the infarct lesion site (without a 12-hour infusion)
reduced infarct size at 30 days in patients with anterior STEMI
reperfused early.
Regarding aspiration thrombectomy, in TAPAS, 1071
patients with anterior and non-anterior STEMI who presented
within 12 h of symptoms at a single-center were randomized
to manual aspiration vs. no aspiration before primary PCI;
aspiration resulted in modest improvements in MBG and STR
but a marked reduction in 1-year mortality. Other trials have
reported conflicting results, and in contrast to single-center
studies, multicenter aspiration trials have been largely neg-
ative. Moreover, in TAPAS, aspiration did not reduce infarct
size as measured by cardiac biomarkers, calling into question
the mechanism underlying the survival benefit. The present
multicenter trial, in which only patients presenting early with
anteriorMI and coronary anatomy optimal for aspirationwere
enrolled, and in which cMRI was used to assess infarct size at
30 days was specifically designed to overcome many of the
limitations from these earlier studies. The fact that manual
thrombus aspiration did not reduce infarct size in this studymakes a substantial clinical benefit unlikely, questioning its
routine use in STEMI.
9. Our opinion
Regarding use of GPIIb/IIIa inhibitors: a) I/V bolus and infusion
is to be discouraged because it achieves very little intra-clot
concentration and also increases the risk of systemic bleed-
ing. b) Only bolus intracoronary drug should be used, that too
not into the guide catheter, but via a clearway catheter (we can
use a simple PTCA balloon by making multiple holes on its
surface, in case clearway catheter is not available).
Regarding manual aspiration via Export catheter: a) the
symptom onset to hospital arrival and the D-to-B time were
substantially shorter in this study which is next to impossible
in our context. b) As time passes by after STEMI thrombus
tends to get organized and hence thrombus aspiration might
have some role to play in late presenters of STEMI. However,
the last word in this matter is yet to be written.
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Objectives: The aim of this study was to evaluate the effi-
cacy of drug-eluting balloons (DEB) compared with paclitaxel
eluting stents (PES) for the reduction of restenosis in small
vessels.
Background: DEB have been shown to be effective in the
treatment of coronary in-stent restenosis, but data are limited
regarding their efficacy in de-novo disease.
Methods:BELLO (BalloonElution and Late LossOptimization)
is a prospective, multicentre trial that randomized 182 patients
with lesions located in small vessels (reference diameter
<2.8 mm) to treatment with paclitaxel DEB and provisional
bare-metal stenting (n ¼ 90) or PES implantation (n ¼ 92). The
primary endpoint was noninferiority of angiographic in-stent
(in-balloon) late loss with a delta of 0.25 mm. Secondary end-
points were angiographic restenosis, target lesion revasculari-
zation, and major adverse cardiac events (MACE; death, myo-
cardial infarction, target vessel revascularization) at 6 months.
Results: Baseline characteristics were well matched,
except for a smaller vessel size in the DEB group
